Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma

Izumi, Miiru; Nakanishi, Yoichi; Yoshino, Ichiro; Nakashima, Mitsuyoshi; Watanabe, Takeshi; Hara, Nobuyuki

doi:10.1002/1097-0142(20010715)92:2<446::aid-cncr1341>3.0.co;2-3

Cited by 60 publications

(56 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Izumi et al (2001) reported that RCAS1 expression was positive for 48 of 102 non-small-cell lung carcinoma patients (47.1%) and was significantly correlated with advanced stage, poor differentiation and poor prognosis. Ito et al (2003) reported that RCAS1 overexpression was more frequently observed in anaplastic carcinomas than well-differentiated carcinoma in thyroid cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription -polymerase chain reaction (RT -PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERa. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERa were evaluated by RT -PCR in 22 cases. The expression for EBAG9 and ERa was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P ¼ 0.0402) and advanced disease (P ¼ 0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P ¼ 0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (Po0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERa mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERa expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Others reported that RCAS1 is associated with poor prognosis and/or advanced stage in various human cancers (Sonoda et al, 1996;Kaku et al, 1999;Izumi et al (2001); Nakakubo et al, 2002). However, the expression of EBAG9 and its clinical significance have not been examined in epithelial ovarian cancer.…”

mentioning

confidence: 99%

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Expression of RCAS1 correlates with invasion or progression in several carcinomas (2,9,10). In addition, RCAS1 expression is associated with poor prognosis in uterine, lung, gallbladder, pancreas, and esophageal carcinoma (11)(12)(13)(14)(15). Although previous studies suggested that RCAS1 is also expressed in colorectal carcinoma cells, the relationship between RCAS1 expression and prognosis in colorectal carcinomas is not known at present.…”

mentioning

confidence: 99%

Expression of Tumor-Associated Membrane Antigen, RCAS1, in Human Colorectal Carcinomas and Possible Role in Apoptosis of Tumor-Infiltrating Lymphocytes

Okada

Nakashima²,

Komuta

et al. 2003

Modern Pathology

Self Cite

View full text Add to dashboard Cite

RCAS1, a novel tumor-associated antigen, is expressed in advanced human neoplasias including uterine and ovarian carcinomas. RCAS1 protein was indicated to induce cell cycle arrest and apoptosis of cultured human lymphoid and myeloid cell lines and normal lymphocytes. In the present study, we investigated the expression and prognostic value of RCAS1 in 58 patients with colorectal carcinomas. RCAS1 protein was detected by immunoperoxidase staining using a mouse monoclonal anti-RCAS1 antibody (22-1-1 antibody). Immunohistochemical examination showed expression of RCAS1 in 75% of colorectal carcinomas with lymph node metastases (n ‫؍‬ 24), whereas it was present in only 41% of tumors without metastases (n ‫؍‬ 34, P < .05). Patients with RCAS1-positive tumors showed a significantly poorer prognosis than those negative for RCAS1 (P < .05). Multivariate analysis using the Cox regression model indicated that RCAS1 positivity was an independent negative predictor for survival (P ‫؍‬ .0300; risk ratio, 0.496). In addition, apoptotic cells of tumor-infiltrating lymphocytes were examined using nonradioactive in situ nick translation in paraffin-embedded sections. The proportion of apoptotic tumor-infiltrating lymphocytes was significantly higher in RCAS1-positive colorectal carcinomas (11.2 ؎ 1.0) than in RCAS1-negative tumors (7.9 ؎ 1.0, P < .05). Our results suggest that overexpression of RCAS1 may negatively affect the prognosis of human colorectal carcinomas and that RCAS1 may play a role in tumor immune privilege in vivo.

show abstract

“…Patients with RCAS1 overexpression had a poorer survival than those with normal RCAS1 expression and those with positive RCAS1 expression (Po0.0001). In previous studies, RCAS1 expression was associated with poorer clinical prognosis for uterine cervical adenocarcinoma and non-small-cell lung carcinoma (Kaku et al, 1999;Iwasaki et al, 2000;Izumi et al, 2001). RCAS1 expression has also been reported to correlate with tumour progression or the invasive tendency of uterine cervical, gastric, skin, and hepatocellular carcinomas (Sonoda et al, 1998;Kubokawa et al, 2001;Noguchi et al, 2001;Takahashi et al, 2001).…”

Section: Discussionmentioning

confidence: 91%

Association between RCAS1 expression and clinical outcome in uterine endometrial cancer

et al. 2003

View full text Add to dashboard Cite

RCAS1, which acts as a ligand for a putative receptor on immune cells such as peripheral lymphocytes and natural killer cells, is strongly expressed in human cancers. RCAS1 can induce these cells to undergo apoptotic cell death, which suggests that RCAS1 expression may prohibit the stromal reaction occurring in a tumour. To clarify the clinical significance of RCAS1 expression in uterine endometrial cancer, we analysed the association between RCAS1 expression and clinicopathologic variables by statistical methods. With the use of immunohistochemical techniques, we performed a retrospective study of RCAS1 expression in resected tumour tissue from 147 patients with uterine endometrial cancer. We evaluated the statistical correlation between RCAS1 expression and clinicopathologic variables. RCAS1 was expressed in 106 of 147 patients with uterine endometrial cancer ; 30 of these 147 patients showed RCAS1 overexpression. Overexpression of RCAS1 was significantly correlated with age at surgery, stage, extent of myometrial invasion, and positive peritoneal cytologic results. Multivariate analysis revealed that RCAS1 expression and metastasis were clinically significant prognostic factors for the overall survival. These findings indicated that analysis for RCAS1 expression can provide crucial information about the clinical behaviour of uterine endometrial cancer, which may be valuable for the management of patients with this disease.

show abstract

Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma

Cited by 60 publications

References 20 publications

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Expression of Tumor-Associated Membrane Antigen, RCAS1, in Human Colorectal Carcinomas and Possible Role in Apoptosis of Tumor-Infiltrating Lymphocytes

Association between RCAS1 expression and clinical outcome in uterine endometrial cancer

Contact Info

Product

Resources

About